A new self-rating scale for detecting atypical or second-generation antipsychotic side effects

Abstract

We aimed to construct and assess a new self rating scale to detect the side effects of second generation antipsychotics. This scale was designed to allow a timely, sensitive and reliable method of gathering information on the number and severity of side effects an individual suffers from. The Glasgow Antipscyhotic Side-effect Scale (GASS) was developed after literature review, discussion with members of the mental health team and with service user feedback. Fifty indivudals taking second generation antipsychotics completed the GASS along with the Liverpool Univeristy Neuroleptic Side Effect Rating Scale, and one week later completed the GASS for a second time. Fifty comparison subjects also completed the GASS. The GASS was shown to have good discrimatory power and construct validity, along with good re-test reliablity, and is put forward as a short, helpful and valid clinical tool.

Keywords

neuroleptic drugs atypical antipsychotics antipsychotic agents/adverse effects drug monitoring questionnaires

Get full access to this article

View all access options for this article.

References

Barnes, TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.

Chouinard, G. , Ross-Chouinard, A. , Annable, L. (1980) Extrapyramidal Rating Scale. Can J Neurol Sci 7: 233-239.

Day, JC , Wood, G. , Dewey, M. , Bentall, RP (1995) A Self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 166: 650-653.

Fleischhaker, W. , Bergmann, K. , Perovich, R. (1989) The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. Psychopharmacol Bull 25: 222-226.

Geddes, J. , Freemantle, N. , Harrison, P. , Bebbington, P. (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J 321: 1371-1376.

Guy, W. (1976) ECDEU assessment manual for psychopharmacology. Revised. Rockville, MD: U.S. Department of Health, Education, and Welfare, Alcohol, Drug Abuse and Mental Health Administration , pp. 534-537.

Hogan, TP , Awad, AG , Eastwood, R. (1983) A self-report predictive of drug compliance in schizophrenia: reliability and discriminative ability. Psychol Med 13: 177-183.

Joint Formulary Committee (2005) British National Formulary, 5 1ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain.

Lambert, M. , Conus, P. , Eide, P. , Mass, R. , Karow, A. , Moritz, S. , Golks, D. , Naber, D. (2004) Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 19: 415-422.

10.

Lieberman, JA , Stroup, TS , McEvoy, JP , Swartz, MS , Rosenheck, RA , Perkins, DO , Keefe, RSE , Davis, SM , Davis, CE , Lebowitz, BD , Severe, J. , Hsiao, JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.

11.

Lingjaerde, O. , Ahlfors, UG , Bech, P. , Dencker, SJ , Elgen, K. (1987) The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs, and a cross sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 76 (Suppl.): 1-100.

12.

Medcalc Software (2006) Mariakerke, Belgium. http://www.medcalc.be.Accesseddate1/11/06.

13.

Negi, R. (2007) A randomized controlled study to determine whether the use of LUNSERS improves clinician awareness. Abstract presented at Royal College of Psychiatrists' General & Community Faculty meeting, Newcastle.

14.

NICE guidelines (2002) Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. http://www.nice.org.uk. Accessed date 15/01/07.

15.

Patel, MP , David, AS (2007) Medication adherence: predictive factors and enhancement strategies. Psychiatry 6: 357-361.

16.

Robinson, DG , Woerner, MG , Alvir, JM , Bilder, RM , Hinrichsen, GA , Lieberman, JA (2002) Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 57: 209-219.

17.

Simpson, GM , Angus, JW (1970) A rating scale for extrapyramidal side effects . Acta Psychiatr Scand 212: 11-19.

18.

Tacchi, MJ , Scott, J. (2005) Improving medication adherence in schizophrenia and bipolar disorders. Chichester: John Wiley & Sons Ltd.

19.

Yusufi, BZ , Mukherjee, S. , Aitchison, K. , Dunn, G. , Page, E. , Barnes, TRE (2005) Reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale (ANNSERS). J Psychopharmacol 19 (Suppl.): A10.